HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment.

Abstract
Diffuse glioma is the deadliest form of brain cancer, and the median survival of grade IV glioma (glioblastoma, GBM) is no more than 2 years even with maximal surgical resection followed by radiotherapy and chemotherapy, which are now the standard of care for GBM. Glioma shares common characteristics with most malignant tumours, such as invasiveness, rapid progression, resistance to various therapies and inevitable recurrence, while it also has its own unique features, such as high aggressiveness and immunotherapy resistance, which can be, respectively, attributed to epithelial-mesenchymal transition (EMT) and the immunosuppressive microenvironment. Here, we calculated the EMT score of glioma using The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA) and the Gene Expression Omnibus (GEO) datasets and validated its prognostic value. Then, we investigated its role in the glioma immune microenvironment, identified the enriched EMT-related immune genes and determined their specific biological functions in glioma. Furthermore, clinical relevance analysis showed the translational value of these EMT-related immune genes. In short, our findings reveal a critical link between EMT and the glioma immune microenvironment and offer important clues for further investigation of the underlying molecular mechanism.
AuthorsWeihai Ning, Zhiqiang Qiu, Xiangwen Ji, Xiang Wang, Yihua An, Shengdian Wang, Hongwei Zhang
JournalJournal of molecular neuroscience : MN (J Mol Neurosci) Vol. 70 Issue 10 Pg. 1501-1511 (Oct 2020) ISSN: 1559-1166 [Electronic] United States
PMID32495005 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • Proteome
Topics
  • Biomarkers, Tumor (genetics, immunology)
  • Brain Neoplasms (genetics, immunology, pathology)
  • Epithelial-Mesenchymal Transition
  • Glioma (genetics, immunology, pathology)
  • Humans
  • Proteome (genetics, metabolism)
  • Transcriptome
  • Tumor Microenvironment (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: